Table 1
Summary of estimated in vivo effective concentration of quinolones required with topical administration. Estimates of tissue concentrations obtained with oral and topical use in ideal conditions
| MIC90 (mg/l) | ||
|---|---|---|
| Ciprofloxacin | Gatifloxacin/moxifloxacin | |
| S pneumoniae | 2 | 0.12–0.5 |
| S aureus (all) | 0.25–2 | 0.06–0.13 |
| MRSA | R | 6.25/2.0 |
| Ps aeruginosa | 0.5(8) | 3–32 |
| Enterobacteriaceae | 0.01–0.25 | 0.01–0.39 |
| Cmax (serum, mg/l) | 2.4500 mg po | 4.2–4.5400/40 mg po |
| Aqueous (mg/l) | 0.69750 mg X3 po | |
| Cornea (mg/l) | 0.60.3% topical | |
